Company Bellerophon Therapeutics, Inc. Börse Stuttgart
Equities
6L7A
US0787713009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.421 EUR | +20.98% | +26.05% | -45.08% |
02/05 | North American Morning Briefing : Stock Futures -2- | DJ |
25/04 | North American Morning Briefing : More Tech -2- | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 29/15/29 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Bobae Kim
LAW | General Counsel | 42 | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 29/15/29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,232,648 | 10,394,477 ( 84.97 %) | 0 | 84.97 % |
Company contact information
Bellerophon Therapeutics, Inc.
184 Liberty Corner Road Suite 302
07059, Warren
+908 574 4770
http://www.bellerophon.comSector
1st Jan change | Capi. | |
---|---|---|
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- BLPH Stock
- 6L7A Stock
- Company Bellerophon Therapeutics, Inc.